The Role of Granulocyte-Macrophage Colony-Stimulating Factor in Murine Models of Multiple Sclerosis

Kelly L Monaghan1, Edwin C K Wan1,2,3

  • 1Department of Microbiology, Immunology, and Cell Biology, West Virginia University, Morgantown, WV 26506, USA.

Cells
|March 8, 2020
PubMed

Insights

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is crucial in multiple sclerosis (MS) pathology, as shown in animal models. Targeting GM-CSF offers a promising therapeutic strategy for MS by modulating immune responses in the central nervous system.

Area of Science:

  • Neuroimmunology
  • Immunology
  • Cell Biology

Background:

  • Multiple sclerosis (MS) is an immune-mediated central nervous system (CNS) disease.
  • Experimental autoimmune encephalomyelitis (EAE) is a key animal model for studying MS pathology.
  • Granulocyte-macrophage colony-stimulating factor (GM-CSF) has emerged as a critical factor in EAE pathogenesis.

Purpose of the Study:

  • To review the role of GM-CSF in maintaining immune homeostasis.
  • To explore GM-CSF signaling in EAE pathology, including cell types and disease phases (acute and chronic).
  • To assess GM-CSF's role in various MS models and its implications for human MS immunopathology.

Main Methods:

  • Literature review of studies on GM-CSF in EAE and other MS models.
  • Analysis of GM-CSF's function in immune cell regulation and CNS inflammation.
  • Examination of clinical trial data targeting GM-CSF in MS patients.

Main Results:

  • GM-CSF plays a critical, non-redundant role in EAE pathology.
  • GM-CSF signaling influences both acute and chronic EAE.
  • Understanding GM-CSF in animal models informs its role in human MS.

Conclusions:

  • GM-CSF is a significant therapeutic target for MS.
  • Targeting GM-CSF may modulate immune responses implicated in MS.
  • Research on GM-CSF has advanced clinical trials for MS treatment.